Skip to main content

A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

October 18, 2023

End Date

October 30, 2028
 

Administered By

Duke Cancer Institute

Awarded By

Incyte Corporation

Start Date

October 18, 2023

End Date

October 30, 2028